Chart, page-4313

I would be truly shocked if ANP management release a quarterly report with not a single mention of or allusion to the EMA approvals. I would imagine if they do, it’ll be because they CANNOT announce yet, in which case I am very happy to pick up more cheap shares. I would imagine if it was a CR, we would have already had it announced.

I’d also like to point out that a single $30M CR would be somewhat foolish as we have multiple trials (FDA parallel preclin/clin 9 month tox, MD phase 2, new proteomics indications), so they’d probably have to do a huge raise for all upcoming trials (seems unlikely) or multiple small raises, which would infuriate shareholders.

I would still maintain we will be seeing some form of partnership that provides ample funding for multiple trials in Europe and the US with another leeway to handle any setbacks (COVID, trial issues, misc additional funding requirements). Fingers crossed for a quarterly + partnership announcement by Friday.